Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elowen-LTE: Long-Term Extension Study of Enpatoran in Lupus Erythematosus
NCT07840287Phase 3Not yet recruiting
- Sponsor
- EMD Serono
- Start
- Oct 2026
- Primary completion
- Sep 2031
- Countries
- 2
01
Overview
A Phase 3 trial of enpatoran in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), sponsored by EMD Serono. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT07840287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840287.